Loading…
Loading…
As of 20 Nov 2026: ALIVUS ₹1,436.90 (m-cap ₹17,674 Cr, P/E 26.3) vs Natco Pharma ₹814.30 (m-cap ₹15,960 Cr, P/E 17.8). Compare ROE, ROCE, growth, debt, dividends and 1-year returns.
As of · NSE prices; ratios from company filings
| Metric | ALIVUS | Natco Pharma |
|---|---|---|
| Share price | ₹1,436.90 | ₹814.30 |
| Day change | −0.90% | −0.93% |
| Market cap | ₹17,674 Cr | ₹15,960 Cr |
| P/EPrice ÷ trailing 12-month earnings per share; blank for a loss. | 26.3 | 17.8 |
| P/BPrice ÷ book value per share. | 4.9 | 1.5 |
| ROEReturn on equity. | 18.1% | 17.1% |
| ROCEReturn on capital employed. | 24.0% | 17.0% |
| Sales growth (3Y CAGR) | 5.7% | 14.6% |
| Profit growth (3Y CAGR) | 5.9% | 27.0% |
| Debt to equity | 0.01 | 0.11 |
| Dividend yield | 0.35% | 0.52% |
| 1-year price return | +57.9% | −4.8% |
| Promoter holding | 74.8% | 46.2% |
| Industry | Pharmaceuticals | Pharmaceuticals |
Open in the compare tool for price charts from one month to five years, scorecards and more companies.
Each line states which company has the higher or lower figure; none of them is a recommendation.
Alivus Life Sciences Ltd is larger, with a market cap of ₹17,674 Cr against ₹15,960 Cr for Natco Pharma Ltd as of 20 Nov 2026 — about 1.1 times the size.
Natco Pharma Ltd trades at a P/E of 17.8 against 26.3 for Alivus Life Sciences Ltd as of 20 Nov 2026. A lower P/E alone does not make a share cheaper in value terms: growth, return on capital and debt differ between companies.
Jivani Markets does not give buy, sell or hold recommendations and is not a SEBI-registered investment adviser or research analyst. The table on this page lays out the facts side by side — price, valuation, returns on capital, growth, debt, dividends and promoter holding — so you can weigh them against your own goals, or with a SEBI-registered adviser.
Prices refresh every few minutes during market hours and ratios update when the companies report results. Each number is the same one shown on the two stock pages.